2013
DOI: 10.1093/annonc/mds529
|View full text |Cite
|
Sign up to set email alerts
|

Abstract: Single-agent erlotinib was active and well tolerated in NSCLC patients with BM. Further studies are warranted.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

8
133
2

Year Published

2016
2016
2023
2023

Publication Types

Select...
7
1

Relationship

0
8

Authors

Journals

citations
Cited by 209 publications
(143 citation statements)
references
References 33 publications
8
133
2
Order By: Relevance
“…Nevertheless radiotherapy did not improve disease response and no significant differences in ORR were documented. In general, cranial irradiation caused a rate of neurological adverse events higher than that reported in studies with TKIs alone (84)(85)(86), but lower than that of the concurrent upfront WBRT/TKIs studies (92,93). By limiting the analysis to prospective studies, there was no significant difference in intracranial disease control and survival outcomes between concurrent upfront WBRT plus TKIs and TKIs alone.…”
Section: Standard Schedulesmentioning
confidence: 82%
See 2 more Smart Citations
“…Nevertheless radiotherapy did not improve disease response and no significant differences in ORR were documented. In general, cranial irradiation caused a rate of neurological adverse events higher than that reported in studies with TKIs alone (84)(85)(86), but lower than that of the concurrent upfront WBRT/TKIs studies (92,93). By limiting the analysis to prospective studies, there was no significant difference in intracranial disease control and survival outcomes between concurrent upfront WBRT plus TKIs and TKIs alone.…”
Section: Standard Schedulesmentioning
confidence: 82%
“…In preclinical mouse model of EGFR mutated NSCLC with BM, gefitinib has proven effective (102). Complete and sustained responses following BM treatment with erlotinib and gefitinib have been reported in several case reports (103)(104)(105)(106) for BM (84)(85)(86)). An open-label, single-institution, phase II study (84) prospectively evaluated the efficacy of EGFRTKIs, erlotinib or gefitinib, in pts with BM from NSCLC harboring EGFR mutations.…”
Section: Standard Schedulesmentioning
confidence: 96%
See 1 more Smart Citation
“…Despite the evidence of a lower rate of central nervous system (CNS) progression in patients treated with EGFR-TKI than in those receiving chemotherapy, brain progression is still the most common site of failure in patients with ALK-rearranged NSCLC during TKI therapy and remains the most important event with an impact on prognosis (19). Recent phase II trials, published in 2012 and 2013, demonstrated the activity of EGFR-TKIs against brain metastasis in a very selected group of patients with EGFR-mutant NSCLC without the upfront use of RT (20,21). Nevertheless, it is important to underline that the cerebrospinal fluid (CSF) penetration ratio (defined as concentration in CSF/concentration in blood) of erlotinib ranges between 2.5% to 13% and for gefitinib from <1% to 10%.…”
Section: Discussionmentioning
confidence: 99%
“…Accumulating evidences have indicated that TKI is also efficient for brain metastases in patients with EGFR mutation. Chinese Thoracic Oncology Group (CTONG) 0803 showed that single-agent erlotinib was active and well tolerated in patients with asymptomatic brain metastases, the median PFS and overall survival were 15.2 and 18.9 months for patients with activating EGFR mutation (40). Encouraged by these findings, and the concern of the potential neurocognitive function in the use of WBRT, CTONG 1201 was initiated to compare the efficacy of TKI (icotinib) versus WBRT with or without chemotherapy in NSCLC patients with EGFR mutation, who were naive to treatment with EGFR-TKIs or radiotherapy, and had at least three metastatic brain lesions.…”
Section: Whole Brain Radiotherapy (Wbrt) and Stereotactic Radiosurgermentioning
confidence: 99%